MA-CENTERITY
22.10.2020 15:02:08 CEST | Business Wire | Press release
Centerity Systems, Inc. , the leading AIOps Platform with advanced performance analytics and integrated security, today announced its recognition as a Top Value Leader in the latest “EMA Radar Report: AIOps – A Guide for Investing in Innovation .”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005664/en/
EMA evaluated 17 AIOps vendors on (i) Business Impact and IT-to-Business Alignment, (ii) Incident, Performance, and Availability Management, and (iii) Change Impact and Capacity Optimization use cases to guide organizations with their AIOps platform selection. Centerity’s AIOps Platform is designated as a market leader in all of the use cases EMA evaluated. Centerity is a front-runner in delivering exceptional value in both the Business Impact and IT-to-Business Alignment and Incident, Performance, and Availability Management use cases, due to its technical strength, impact on business outcomes, and deployment cost efficiency. In addition, Centerity was honored by EMA with a special award for advanced integrated security functionality.
The Centerity AIOps Platform improves performance and reliability of business and operational processes, employing an approach that continuously measures the overall health of key technology services by providing real-time, consolidated business analytics. SLA executive dashboards expose business and security risks, identify performance anomalies, and provide fault isolation across applications, operating systems, infrastructure and cloud assets. It does this by automating topology and dependency maps of all IT assets, incorporating each asset into business and operational service views. Its AI-driven anomaly detection and multi-tenancy supports multi-user, multi-vendor, and multi-location management, which is ideal for managed service providers, cloud service providers, and enterprises.
“Centerity is a unique innovator in the AIOps arena,” said Dennis Drogseth, EMA vice president. “Centerity stands out for its advancing use of AI/ML in a variety of contexts, including ‘CyberOps,’ as well as its distinctive strengths in discovery across domains, data assimilation, and unifying views and dashboards. These strengths, along with the platform’s fast time to value and limited administrative overhead all help to make Centerity both a versatile and progressive choice for AIOps adopters.” According to EMA’s evaluation, the Centerity AIOps platform is differentiated among its competitors by:
-
Delivering many of the benefits of larger and more costly AIOps suites with reduced administrative overhead and more modest software costs.
-
Bringing the full seven-layer stack together with an eye toward IT service performance and business outcomes and priorities across cloud, hybrid, and legacy environments.
- Integrating artificial intelligence and machine learning capabilities to support security and risk management needs – such as cybersecurity compliance, endpoint detection and response (EDR), supply chain security, and automated prevention of attacks on network hardware.
According to EMA, the message for IT organizations looking to pursue a forward path in AIOps adoption is overall a strongly positive one. The benefits achieved are growing in diversity and value. AIOps can and should be transformative in enabling more effective decision-making, data sharing, and analytics-driven automation. The recommendation from EMA remains that buyers should consider their own realities, then begin a search for the AIOps platform that most fits their requirements.
“In the digital age, AIOps, security and risk management must be observed and correlated through a single platform,” said Roi Keren, CEO of Centerity Systems. “That’s not only what we see our customers need and want, it’s what Centerity does best. EMA’s positioning of Centerity and award for integrated security acknowledges the convergence of AIOps and security. It’s more critical than ever for enterprise executives – whether you’re a CIO, CISO, CEO, or board member -- to make strategic, risk-based business decisions with one platform, one dashboard; in essence, a single source of truth.”
AIOps Deployments and the Real Word: Bringing Operations and Security Together
Enterprises can see how others are deploying AIOps to address a variety of use cases by viewing a live EMA-hosted webcast titled “AIOps Deployments and the Real World: Bringing Operations and Security Together ,” which will be held on Tuesday, November 10th at 1:00 pm EST. You can register for the webcast at https://info.enterprisemanagement.com/aiops-deployments-in-the-real-world-webinar-centerity .
About Centerity
Centerity’s Cyber-AIOps Platform with advanced Integrated Security delivers Dynamic Business Service Views of the full technology stack to the executives responsible for technology-driven business services, ensuring the performance, availability and security of critical processes. Centerity displays real-time, consolidated business analytics for complex on-prem, cloud, and hybrid technology environments generating SLA Executive Dashboards that identify performance anomalies and isolate faults across applications, operating systems, infrastructure and cloud assets. Learn more at centerity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005664/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
